Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Biogen presented Phase 2 CELIA study data for diranersen in early Alzheimer’s disease, demonstrating meaningful clinical outcomes and robust tau reduction across all studied doses. Although the study did not meet its primary endpoint of dose response on CDR-SB, the 60 mg dose achieved a 26% slowing of clinical decline on CDR-SB and 42% slowing on ADAS-Cog13, alongside a 50–65% reduction in CSF total tau.
Key figures
- Drug Name
- diranersen (BIIB080)
- Phase Of Trial
- Phase 2
- Study enrollment
- 416
- Mmse slowing 60mg
- 50%
- Cdrsb slowing 60mg
- 26%
- Csf tau reduction mean
- 50–65%
- Adas cog13 slowing 60mg
- 42%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.